List of Excipients in Branded Drug BACTRIM DS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	BACTRIM DS	sulfamethoxazole and trimethoprim	49708-146	DOCUSATE SODIUM
Sun Pharmaceutical Industries Inc	BACTRIM DS	sulfamethoxazole and trimethoprim	49708-146	MAGNESIUM STEARATE
Sun Pharmaceutical Industries Inc	BACTRIM DS	sulfamethoxazole and trimethoprim	49708-146	SODIUM BENZOATE
Sun Pharmaceutical Industries Inc	BACTRIM DS	sulfamethoxazole and trimethoprim	49708-146	SODIUM STARCH GLYCOLATE TYPE A POTATO
Sun Pharmaceutical Industries Inc	BACTRIM DS	sulfamethoxazole and trimethoprim	49708-146	STARCH, CORN
Physicians Total Care Inc	BACTRIM DS	sulfamethoxazole and trimethoprim	54868-0337	DOCUSATE SODIUM
Physicians Total Care Inc	BACTRIM DS	sulfamethoxazole and trimethoprim	54868-0337	MAGNESIUM STEARATE

Bactrim DS Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Bactrim DS is a mature fixed-dose combination tablet containing sulfamethoxazole 800 mg and trimethoprim 160 mg. Its commercial value is no longer based on composition-of-matter exclusivity. The opportunity is in reliable generic supply, cost-controlled excipient sourcing, improved dissolution, patient-friendly dosage forms, and differentiated formulations that can support an ANDA or 505(b)(2) strategy. The core tablet uses a conventional excipient system with limited formulation complexity, which lowers manufacturing barriers but also limits the strength of formulation-based exclusivity.

What is Bactrim DS and which excipients does it contain?

Bactrim DS is an oral double-strength tablet containing 800 mg of sulfamethoxazole and 160 mg of trimethoprim. The product is used for selected bacterial infections, including urinary tract infections, respiratory infections, shigellosis, and Pneumocystis jirovecii pneumonia, subject to labeling restrictions and antimicrobial stewardship considerations.[1]

The FDA-approved product labeling identifies the following inactive ingredients:

Excipient	Primary formulation role	Commercial relevance
Povidone	Binder and granulation aid	Supports tablet strength and granule formation
Sodium starch glycolate	Superdisintegrant	Promotes tablet breakup and dissolution
Magnesium stearate	Lubricant	Improves ejection and manufacturing efficiency
Docusate sodium	Wetting agent and surfactant	Supports powder wetting and may improve dissolution
Tablet coating or finishing materials	Appearance, handling, identification	May affect branding and patient acceptability

The exact excipient composition can differ among authorized manufacturers and generic products. Suppliers must verify the current FDA label and inactive ingredient record for each marketed presentation before relying on a specific formulation.[1,2]

How does the Bactrim DS excipient system work?

The formulation is designed around a conventional compressed-tablet architecture. Povidone provides binding during wet granulation or another granule-forming process. Sodium starch glycolate promotes rapid tablet disintegration after administration. Magnesium stearate reduces sticking and improves tablet ejection. Docusate sodium can improve wetting of hydrophobic drug particles.

The active pharmaceutical ingredients create the central technical challenge. Sulfamethoxazole has limited aqueous solubility, while trimethoprim has pH-dependent solubility. The formulation must therefore balance:

• Granule strength and tablet hardness
• Disintegration time
• Drug dissolution
• Lubrication efficiency
• Content uniformity for the 160 mg trimethoprim component
• Stability under humidity and temperature stress
• Manufacturing throughput

Excessive magnesium stearate can create hydrophobic surfaces and slow dissolution. Excessive compression force can produce a hard tablet with delayed disintegration. Excessive binder can reduce porosity. A competitive formulation program should optimize the full process, not simply substitute one excipient for another.

What formulation opportunities exist for Bactrim DS generics?

The strongest near-term opportunity is a bioequivalent generic tablet with lower manufacturing cost and reliable dissolution performance. The active ingredients are established, and the formulation architecture is familiar to generic manufacturers. The commercial challenge is price competition rather than technical uncertainty.

Direct-compression versus wet-granulation strategies

A direct-compression process can reduce equipment requirements, solvent use, drying time, and manufacturing cost. Its limitations include poor flow, segregation risk, and sensitivity to differences in particle size and bulk density between sulfamethoxazole and trimethoprim.

Wet granulation can improve blend uniformity and tablet robustness. It adds processing steps and may increase exposure to moisture, which requires control of drying endpoints and stability.

A practical strategy is to evaluate:

1. Co-processed excipients for flow and compactibility.
2. Particle-size control for both active ingredients.
3. Low-level binder systems that preserve rapid disintegration.
4. Controlled lubricant blending to limit dissolution impact.
5. Moisture-protective packaging where stability data justify the cost.

Dissolution-focused excipient development

Docusate sodium is commercially important because wetting can be a limiting step for a poorly soluble active. A manufacturer may examine alternative wetting agents or combinations involving surfactants, but any change must maintain acceptable safety, dissolution, impurity, and bioequivalence performance.

Potential development variables include:

• Sodium lauryl sulfate at a controlled concentration
• Poloxamers or other wetting agents
• Crospovidone as an alternative or complement to sodium starch glycolate
• Low-substituted hydroxypropyl cellulose
• Spray-dried or co-processed excipient systems
• Controlled particle-size distributions for the active ingredients

A formulation that dissolves faster in vitro is not automatically commercially superior. FDA approval depends on the applicable product-specific guidance, comparative dissolution, pharmaceutical equivalence, bioequivalence, manufacturing controls, and stability data.[3]

What dosage-form opportunities can compete with Bactrim DS tablets?

Oral suspension

An oral suspension can address patients who cannot swallow tablets. This creates a potential product opportunity, but the formulation must manage taste, sedimentation, redispersibility, preservative performance, viscosity, and chemical stability.

Sulfamethoxazole and trimethoprim have strong and distinctive taste characteristics. Taste masking may require:

• Polymer coating of drug particles
• Ion-exchange resins
• Complexation
• Sweetener and flavor systems
• Viscosity control
• pH adjustment within stability and tolerability limits

The suspension market may offer better differentiation than another standard tablet, particularly for pediatric or institutional use. The development burden is higher because the product must demonstrate dose uniformity throughout the container, acceptable redispersion, microbial quality, and an appropriate in-use period.

Orally disintegrating tablet

An orally disintegrating tablet could target patients with dysphagia and improve administration convenience. The high total drug load, approximately 960 mg before excipients, makes an ODT technically difficult. Tablet size, friability, mouthfeel, taste, and disintegration time would constrain the product.

An ODT may be more practical at a lower strength or as a two-tablet regimen, but that could weaken the convenience proposition and create dose-administration risk.

Smaller tablets or multiparticulates

A smaller unit dose administered as multiple tablets could improve swallowability. Multiparticulate systems may provide better dose flexibility, but they introduce additional coating, segregation, packaging, and content-uniformity requirements. This approach is more likely to support a 505(b)(2) or differentiated product strategy than a standard ANDA, depending on the reference product and proposed changes.

Improved packaging

Packaging is a lower-risk commercial opportunity. Moisture-resistant blistering, unit-dose packaging, and calendarized adherence packs can support hospital, long-term-care, and outpatient pharmacy channels. Packaging alone generally provides limited patent value, but it can reduce waste, medication errors, and handling costs.

What patents protect Bactrim DS and when does exclusivity end?

Bactrim DS is a small-molecule combination product with a long commercial history. Its original regulatory and patent exclusivities expired many years ago. It does not have biosimilar exclusivity issues because it is not a biologic.

The relevant intellectual-property position is therefore more likely to involve:

• Formulation patents for later-developed products
• Manufacturing-process patents
• Crystalline or particle-engineering claims
• Taste-masking or suspension technology
• Packaging or device claims
• Trademarks and trade dress
• Supplier know-how and manufacturing controls

A generic manufacturer should not assume that the absence of active-ingredient patents eliminates all freedom-to-operate risk. The risk must be assessed against current Orange Book listings, published patent documents, litigation databases, and formulation-specific claims. The FDA Orange Book identifies patents and regulatory exclusivities associated with listed drug products when applicable.[4]

For the legacy Bactrim DS tablet, the principal commercial barrier is not a surviving composition-of-matter patent. It is the ability to meet quality requirements at a sustainable cost while competing against established generic suppliers.

What is the Orange Book and FDA regulatory status of Bactrim DS?

Bactrim DS is an FDA-approved prescription drug product. The product is associated with the sulfamethoxazole/trimethoprim fixed-dose combination and is regulated as a conventional small-molecule drug, not as a biologic.[1,4]

A generic manufacturer would generally evaluate an ANDA pathway if it can demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference listed drug. A materially different dosage form, route, formulation, or clinical use may require a 505(b)(2) application rather than a conventional ANDA.[5]

Key regulatory considerations include:

Issue	Relevance to Bactrim DS
Strength	800 mg sulfamethoxazole and 160 mg trimethoprim
Dosage form	Immediate-release oral tablet
Reference standard	Must be confirmed in current FDA databases
Bioequivalence	Required for an ANDA
Dissolution	Important because of active solubility and wetting behavior
Stability	Required for proposed packaging and shelf life
Labeling	Must address serious hypersensitivity and other safety restrictions
Pediatric use	Relevant to suspension and taste-masking opportunities
Drug interactions	Important for prescribing, labeling, and medical-information support

The reference product, dosage form, and current FDA product-specific requirements should control development decisions. A formulation that copies the excipient list but changes excipient grade, process, particle size, or lubricant exposure may still produce different dissolution or bioequivalence results.

Which companies are challenging Bactrim DS commercially?

Competition is primarily among generic manufacturers and contract suppliers rather than branded innovators. The relevant competitive groups include:

• Large generic companies with national pharmacy distribution
• Regional generic manufacturers
• Contract manufacturing organizations
• Hospital-focused suppliers
• Specialty manufacturers offering oral suspensions or unit-dose packaging

The market is vulnerable to supply disruption because trimethoprim/sulfamethoxazole is a mature, relatively low-margin antibiotic. Manufacturers with multiple qualified API sources, redundant tablet sites, and stable excipient supply have an advantage over companies relying on a single source.

A new entrant should compete on at least one measurable variable:

• Lower cost per tablet
• Better supply reliability
• Hospital contract pricing
• Unit-dose presentation
• Pediatric suspension availability
• Improved packaging
• Lower tablet weight or improved swallowability
• Regional distribution speed

A standard Bactrim DS tablet without a cost or supply advantage is unlikely to obtain durable pricing power.

How strong is the Bactrim DS formulation patent estate?

The legacy formulation estate is commercially weak relative to newer drugs because the product has been marketed for decades and generic competition is established. Any residual patent opportunity would more likely arise from a new formulation or delivery technology than from the conventional excipient combination.

Patentable areas may include:

• Narrow excipient concentration ranges tied to dissolution performance
• Specific particle-size distributions
• Coated or taste-masked particles
• Stable liquid suspensions
• New preservative systems
• Modified-release delivery
• Unit-dose packaging with stability benefits
• Manufacturing processes that reduce impurity formation

The strongest claims would need a defensible technical effect, such as improved stability, reproducible dissolution, reduced degradation, or clinically meaningful administration advantages. Broad claims covering routine use of povidone, sodium starch glycolate, magnesium stearate, or docusate sodium would face substantial prior-art risk.

What generic launch risks exist for Bactrim DS?

Paragraph IV challenges

A Paragraph IV certification could arise if an ANDA applicant addresses a listed patent. Given the age of the product, the more relevant risk is that a later formulation or delivery product has its own patent listings. A generic applicant must review listed patents and determine whether to certify invalidity, unenforceability, noninfringement, or expiration.

Litigation and settlement agreements

The commercial record for legacy Bactrim DS is more likely to involve historical generic entry and routine product disputes than active high-value patent litigation. Any settlement analysis must be based on current court dockets and FDA records. A generic manufacturer should not rely on historical market entry dates as evidence of current freedom to launch.

Manufacturing and supply barriers

The main operational risks are:

• API supplier qualification
• Blend uniformity at the low trimethoprim fraction
• Dissolution variability
• Tablet sticking and picking
• Lubricant overmixing
• Humidity-related stability
• Packaging component availability
• FDA inspection findings
• Voluntary recalls affecting reputation and contracts

These risks can have greater commercial impact than patent litigation in a mature antibiotic market.

What licensing deals could create value?

Licensing opportunities are more plausible for technology than for the Bactrim DS brand itself. Potential targets include:

• Taste-masking platforms for sulfamethoxazole/trimethoprim suspension
• Co-processed excipients that improve high-dose tablet compression
• Particle-engineering technology
• Pediatric delivery systems
• Moisture-barrier packaging
• Contract manufacturing capacity with validated combination-tablet processes

A license should be evaluated against the incremental margin it creates. For a low-priced generic tablet, a royalty-bearing excipient or delivery technology may destroy economics unless it supports a differentiated product, institutional contract, or regulatory exclusivity strategy.

How does Bactrim DS compare with competing antibiotic opportunities?

Product opportunity	Formulation complexity	Patent potential	Margin potential	Primary risk
Standard Bactrim DS tablet	Low to moderate	Low	Low	Price competition
Bactrim DS oral suspension	Moderate to high	Moderate	Moderate	Taste and stability
Bactrim DS ODT	High	Moderate	Moderate	High drug load
Unit-dose hospital packaging	Low	Low	Low to moderate	Contract concentration
Novel modified-release product	High	Higher	Potentially higher	Clinical and regulatory burden
Alternative antibiotic generic	Varies	Varies	Varies	API and market crowding

Bactrim DS is most attractive as a supply-chain and formulation-optimization project, not as a conventional exclusivity play.

Key Takeaways

• Bactrim DS contains sulfamethoxazole 800 mg and trimethoprim 160 mg.
• Its conventional excipients include povidone, sodium starch glycolate, magnesium stearate, and docusate sodium.
• The main technical objective is to balance wetting, dissolution, tablet strength, disintegration, and manufacturing cost.
• Original product exclusivity has expired; the product is exposed to generic competition.
• Standard tablet entry offers limited pricing power.
• Oral suspension, pediatric taste masking, unit-dose packaging, and supply reliability offer stronger commercial differentiation.
• Bactrim DS has no biosimilar risk because it is a small-molecule drug.
• Formulation patents would need a specific technical effect to withstand prior-art and obviousness challenges.
• Manufacturing reliability and API sourcing are likely to matter more than legacy patent barriers.
• Licensing is most attractive for delivery, taste-masking, particle-engineering, or packaging technology.

FAQs

Is Bactrim DS an immediate-release tablet?

Yes. Bactrim DS is marketed as an oral immediate-release tablet containing 800 mg sulfamethoxazole and 160 mg trimethoprim.[1]

Can a generic manufacturer use the same Bactrim DS excipients?

A generic manufacturer may use the same inactive ingredients if the formulation complies with applicable FDA requirements. It is not required to duplicate the reference product’s excipient system in every case, but the proposed product must meet pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.

Which excipient is most important for Bactrim DS dissolution?

Docusate sodium can be important for wetting, while sodium starch glycolate is important for tablet disintegration. The outcome depends on concentration, mixing order, active-particle properties, compression force, and lubricant exposure.

Is a Bactrim DS oral suspension commercially attractive?

It can be more differentiated than a standard tablet because it addresses swallowing difficulty and pediatric administration. The main development risks are taste, sedimentation, redispersibility, preservative performance, and dose uniformity.

Does Bactrim DS have biosimilar competition?

No. Bactrim DS is a conventional small-molecule fixed-dose combination. Competitive products are generic drugs submitted through the ANDA pathway or, for materially changed products, potentially the 505(b)(2) pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Bactrim DS: Sulfamethoxazole and trimethoprim tablet prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2015). Product-specific guidance for sulfamethoxazole; trimethoprim. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). Center for Drug Evaluation and Research.